{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:54:11Z","timestamp":1793861651116,"version":"4.6.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Janssen Vaccines & Prevention"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) and influenza cause significant disease burden in older adults. Overlapping RSV and influenza seasonality presents the opportunity to coadminister vaccines for both infections. This study assessed coadministration of the investigational vaccine, Ad26.RSV.preF, an adenovirus serotype 26 (Ad26) vector encoding RSV F protein stabilized in its prefusion conformation (pre-F), with a seasonal influenza vaccine in older adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this phase 2a, double-blind, placebo-controlled study, 180 adults aged \u226560 years received Ad26.RSV.preF plus Fluarix on day 1 and placebo on day 29, or placebo plus Fluarix on day 1 and Ad26.RSV.preF on day 29 (control).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The coadministration regimen had an acceptable tolerability profile. Reactogenicity was generally higher after Ad26.RSV.preF versus Fluarix, but symptoms were generally transient and mild or moderate. At 28 days after the first vaccination, the upper confidence intervals of the hemagglutination inhibition antibody geometric mean ratio (control\/coadministration) for all influenza strains were &amp;lt;2, demonstrating noninferiority. Robust neutralizing and binding antibody responses to RSV A2 were observed in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Coadministration of Fluarix with Ad26.RSV.preF vaccine had an acceptable safety profile and showed no evidence of interference in immune response. The results are compatible with simultaneous seasonal vaccination with both vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03339713.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa409","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T11:09:14Z","timestamp":1598440154000},"page":"699-708","source":"Crossref","is-referenced-by-count":48,"title":["Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults"],"prefix":"10.1093","volume":"223","author":[{"given":"Jerald","family":"Sadoff","sequence":"first","affiliation":[{"name":"Janssen Vaccines & Prevention, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"De Paepe","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Haazen","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Omoruyi","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arangassery R","family":"Bastian","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Comeaux","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Heijnen","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Strout","sequence":"additional","affiliation":[{"name":"Coastal Carolina Research Center, Mount Pleasant, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2021022419582729000_CIT0001","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1017\/S0950268807007881","article-title":"Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods","volume":"135","author":"Fleming","year":"2007","journal-title":"Epidemiol Infect"},{"key":"2021022419582729000_CIT0002","doi-asserted-by":"crossref","first-page":"ofw270","DOI":"10.1093\/ofid\/ofw270","article-title":"Hospitalizations for respiratory syncytial virus among adults in the United States, 1997\u20132012","volume":"4","author":"Pastula","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021022419582729000_CIT0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/187152612800100116","article-title":"Respiratory syncytial virus infection in adult populations","volume":"12","author":"Walsh","year":"2012","journal-title":"Infect Disord Drug Targets"},{"key":"2021022419582729000_CIT0004","first-page":"211","article-title":"Consequences of immature and senescent immune responses for infection with respiratory syncytial virus","volume":"372","author":"Malloy","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"2021022419582729000_CIT0005","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"key":"2021022419582729000_CIT0006","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccm.2016.11.010","article-title":"Respiratory syncytial virus infection: an illness for all ages","volume":"38","author":"Walsh","year":"2017","journal-title":"Clin Chest Med"},{"key":"2021022419582729000_CIT0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/314567","article-title":"Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden","volume":"179","author":"Han","year":"1999","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"2021022419582729000_CIT0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/jis309","article-title":"Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults","volume":"206","author":"Widmer","year":"2012","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/cid\/cit471","article-title":"High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections","volume":"57","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021022419582729000_CIT0011","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1086\/511986","article-title":"Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?","volume":"195","author":"Walsh","year":"2007","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0012","first-page":"747","article-title":"The diagnosis of viral respiratory disease in older adults","volume":"50","author":"Talbot","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021022419582729000_CIT0013","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0140-6736(01)06488-1","article-title":"Overlap between respiratory syncytial virus infection and influenza","volume":"358","author":"Simoes","year":"2001","journal-title":"Lancet"},{"key":"2021022419582729000_CIT0014","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/infdis\/jit839","article-title":"Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness","volume":"209","author":"Falsey","year":"2014","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/172.2.389","article-title":"Respiratory syncytial virus and influenza A infections in the hospitalized elderly","volume":"172","author":"Falsey","year":"1995","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0016","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"2021022419582729000_CIT0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","article-title":"Novel antigens for RSV vaccines","volume":"35","author":"Graham","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"2021022419582729000_CIT0018","doi-asserted-by":"crossref","first-page":"e1005554","DOI":"10.1371\/journal.ppat.1005554","article-title":"Antigenic fingerprinting following primary RSV infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins","volume":"12","author":"Fuentes","year":"2016","journal-title":"PLoS Pathog"},{"key":"2021022419582729000_CIT0019","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F\u2013 specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021022419582729000_CIT0020","doi-asserted-by":"crossref","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci Immunol"},{"key":"2021022419582729000_CIT0021","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021022419582729000_CIT0022","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2021022419582729000_CIT0023","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"key":"2021022419582729000_CIT0024","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41467-017-01092-4","article-title":"Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV","volume":"8","author":"Steff","year":"2017","journal-title":"Nat Commun"},{"key":"2021022419582729000_CIT0025","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine development for respiratory syncytial virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr Opin Virol"},{"key":"2021022419582729000_CIT0027","doi-asserted-by":"crossref","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","article-title":"Strategic priorities for respiratory syncytial virus (RSV) vaccine development","volume":"31","author":"Anderson","year":"2013","journal-title":"Vaccine"},{"key":"2021022419582729000_CIT0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"2021022419582729000_CIT0029","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1586\/erv.11.120","article-title":"Respiratory syncytial virus vaccine development","volume":"10","author":"Hurwitz","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"2021022419582729000_CIT0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"2021022419582729000_CIT0031","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"2021022419582729000_CIT0032","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-019-0150-4","article-title":"Adenovectors encoding RSV F-protein induce durable and mucosal immunity in macaques after two intramuscular administrations","volume":"4","author":"Salisch","year":"2019","journal-title":"NPJ Vaccine"},{"key":"2021022419582729000_CIT0033","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding pre-fusion F (Ad26.RSV.preF) in adults 60 years and over","volume":"222","author":"Williams","year":"2020","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0034","first-page":"54917","article-title":"Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventative vaccine clinical trials; availability","volume":"72","author":"Food and Drug Administration.","year":"2007","journal-title":"Fed Reg"},{"key":"2021022419582729000_CIT0035","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"2021022419582729000_CIT0036","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/1471-2334-13-343","article-title":"Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged \u226518 years","volume":"13","author":"Kieninger","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2021022419582729000_CIT0037","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"key":"2021022419582729000_CIT0038","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiv406","article-title":"A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age","volume":"213","author":"Glenn","year":"2016","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0039","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"2021022419582729000_CIT0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"2021022419582729000_CIT0041","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS One"},{"key":"2021022419582729000_CIT0042","doi-asserted-by":"crossref","first-page":"e0174728","DOI":"10.1371\/journal.pone.0174728","article-title":"Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform","volume":"12","author":"Salisch","year":"2017","journal-title":"PLoS One"},{"key":"2021022419582729000_CIT0043","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1016\/j.vaccine.2009.07.106","article-title":"Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys","volume":"27","author":"Rodr\u00edguez","year":"2009","journal-title":"Vaccine"},{"key":"2021022419582729000_CIT0044","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"Hoft","year":"2012","journal-title":"Vaccine"},{"key":"2021022419582729000_CIT0045","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"Ou\u00e9draogo","year":"2013","journal-title":"PLoS One"},{"key":"2021022419582729000_CIT0046","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)","volume":"207","author":"Barouch","year":"2013","journal-title":"J Infect Dis"},{"key":"2021022419582729000_CIT0047","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2021022419582729000_CIT0048","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ppul.10288","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease in 2000\u20132001: results from the palivizumab outcomes registry","volume":"35","author":"Parnes","year":"2003","journal-title":"Pediatr Pulmonol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa409\/33687042\/jiaa409.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/4\/699\/36355755\/jiaa409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/4\/699\/36355755\/jiaa409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T19:59:10Z","timestamp":1614196750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/4\/699\/5897745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,8,26]]},"published-print":{"date-parts":[[2021,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa409","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,15]]},"published":{"date-parts":[[2020,8,26]]}}}